title: Pharmacological investigation of the role of leukotrienes in the pathogenesis of experimental NSAID gastropathy.
abstract: The role of leukotrienes in the pathogenesis of acute gastric ulceration induced by nonsteroidal antiinflammatory drugs was investigated using a rat model. One part of the study involved oral pretreatment with a leukotriene synthesis inhibitor 1 h prior to administration of indomethacin (20 mg/kg per os). Three hours after indomethacin, the extent of macroscopically visible gastric damage was determined, and gastric LTB4 synthesis was determined. The compounds tested were PF-5901, A-64077, nordihydroguaiaretic acid, and L-698,037. Each compound produced dose-related inhibition of gastric LTB4 synthesis and a parallel reduction in the severity of indomethacin-induced damage. The antioxidant properties of these compounds was assessed using an in vitro assay. There was no correlation between the antioxidant properties of the compounds and their ability to reduce the severity of indomethacin-induced gastric damage. In the second part of the study, the effects of intravenous, administration of LTD4 and LTB4 receptor antagonists on indomethacin-induced gastric epithelial damage (measured by permeability to [51Cr]EDTA) were assessed. The two LTD4 receptor antagonists (MK-571 and ICI-204,219) significantly reduced the permeability changes induced by indomethacin, while the two LTB4 antagonists (SC-41930 and LY-255,283) were without significant effect. Despite the reduction of gastric epithelial injury, blockade of LTD4 receptors did not markedly affect the extent of macroscopically visible injury. These data are consistent with the hypothesis that leukotrienes contribute to the epithelial injury and macroscopically visible damage induced by NSAIDs. However, it remains unclear to what extent leukotrienes are involved in the initiation of the injury, as opposed to its amplification.
authors.affiliation: Gastrointestinal Research Group, Faculty of Medicine, University of Calgary, Alberta, Canada.
authors.forename: P M
authors.initials: PM
authors.lastname: Vaananen
authors.forename: C M
authors.initials: CM
authors.lastname: Keenan
authors.forename: M B
authors.initials: MB
authors.lastname: Grisham
authors.forename: J L
authors.initials: JL
authors.lastname: Wallace
mesh_terms: D058927:5-Lipoxygenase-Activating Proteins; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000633:toxicity*; D000975:Antioxidants / Q000494:pharmacology; D001578:Benzopyrans / Q000494:pharmacology; D002352:Carrier Proteins / Q000037:antagonists & inhibitors; D016166:Free Radical Scavengers; D005753:Gastric Mucosa / Q000187:drug effects / Q000473:pathology; D006918:Hydroxyurea / Q000031:analogs & derivatives / Q000494:pharmacology; D007211:Indoles; D007213:Indomethacin / Q000037:antagonists & inhibitors* / Q000633:toxicity; D020024:Leukotriene Antagonists; D007975:Leukotriene B4 / Q000096:biosynthesis; D015289:Leukotrienes / Q000502:physiology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology*; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D008565:Membrane Proteins / Q000037:antagonists & inhibitors; D009930:Organic Chemicals; D010539:Permeability / Q000187:drug effects; D048448:Phenylcarbamates; D011422:Propionates / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors; D018077:Receptors, Leukotriene; D018102:Receptors, Leukotriene B4; D016037:Single-Blind Method; D013276:Stomach Ulcer / Q000139:chemically induced* / Q000503:physiopathology / Q000517:prevention & control; D013449:Sulfonamides; D013777:Tetrazoles / Q000494:pharmacology; D014105:Tosyl Compounds / Q000494:pharmacology
chemical_list: D058927:5-Lipoxygenase-Activating Proteins; C548594:Alox5ap protein, rat; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D001578:Benzopyrans; D002352:Carrier Proteins; D016166:Free Radical Scavengers; D007211:Indoles; C076108:L 698037; D020024:Leukotriene Antagonists; D015289:Leukotrienes; D016859:Lipoxygenase Inhibitors; D008565:Membrane Proteins; D009930:Organic Chemicals; D048448:Phenylcarbamates; D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; D018102:Receptors, Leukotriene B4; D013449:Sulfonamides; D013777:Tetrazoles; D014105:Tosyl Compounds; C049740:alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol; C059950:SC 41930; D007975:Leukotriene B4; C059141:verlukast; D009637:Masoprocol; C063823:LY 255283; C063449:zileuton; D006918:Hydroxyurea; D007213:Indomethacin; C062735:zafirlukast